01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 05, 2024 07:00 ET | Praxis Precision Medicines, Inc.
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
March 01, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024 16:00 ET | Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
January 11, 2024 07:30 ET | Praxis Precision Medicines, Inc.
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
January 10, 2024 16:19 ET | Praxis Precision Medicines, Inc.
BOSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
January 08, 2024 08:00 ET | Praxis Precision Medicines, Inc.
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
January 05, 2024 08:00 ET | Praxis Precision Medicines, Inc.
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
November 28, 2023 07:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023 16:00 ET | Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
November 16, 2023 08:00 ET | Praxis Precision Medicines, Inc.
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsi